Tekirdağ Namık Kemal University is a public university in Tekirdağ, Turkey. The university was founded 2006 under the administration of the Trakya University Rectorate Enver Duran. The university is based on a strong background of 16 years.

During the past decade, Namik Kemal University conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 3 clinical trials were completed, i.e. on average, 15.8% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 3 clinical trials were completed. i.e. 23.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Namik Kemal University" #1 sponsor was "Namik Kemal University" with 9 trials, followed by "BeiGene" with 2 trials sponsored, "Asoc. Prof. Erdoğan Selçuk Şeber" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Namik Kemal University" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Namik Kemal University" are "Breast Cancer" (2 trials), "Advanced or Metastatic Gastric or Gastroesophageal Cancer" (1 trials), "Advanced or Metastatic Solid Tumor" (1 trials), "Anxiety" (1 trials) and "Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors" (1 trials). Many other conditions were trialed in "Namik Kemal University" in a lesser frequency.

Most popular intervention types in "Namik Kemal University" are "Drug" (12 trials), "Procedure" (4 trials), "Other" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (1 trials), "Avelumab Weekly" (1 trials), "Azacitidine" (1 trials), "Capecitabine" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Namik Kemal University" are 15 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Namik Kemal University". 1 are not yet recruiting, 4 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Namik Kemal University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Namik Kemal University, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".

Namik Kemal University has several departments that took part in Clinical trials: "Namık Kemal University Medical Faculty" - 3 trials